June 2015, Vol 4, No 3
The Increasingly Important Role of Pathology in Oncology Patient Care
We are pleased to offer this issue of Personalized Medicine in Oncology (PMO) to you, our reading community. Since the onset of the personalized medicine era, we have repeatedly heard about the importance of the multidisciplinary team to include physicians, nurses, pharmacists, pathologists, social workers, and patients. Of late, we have been intrigued by the growing role of the pathologist. This era of breakthroughs in genetic medicine has placed pathologists at the forefront, delivering essential diagnostic clinical data to help determine the best treatment options for patients. There has been much debate over the proposal by the FDA to regulate laboratory developed tests. In this issue of PMO, the Interview with the Innovators department features our exchange with Drs Klein and Pratt of the Association for Molecular Pathology about the implications of this proposal.
Also in this issue, Ms Tsui and Dr Reckamp contribute their paper entitled â€śExpanding Options for EGFR-Mutant Nonâ€“Small Cell Lung Cancer with Afatinib,â€ť and we continue to explore the changing landscape of oncology care through the fascinating science behind oncogenic driver mutations and their implications for patient care. Drs Yeh and Bazhenova at the University of California, San Diego, present â€śBRAF Mutations: An Old Oncogene and a New Target in Nonâ€“Small Cell Lung Cancerâ€ť; and Drs Shatsky and Bazhenova present â€śThe RET Oncogene in Nonâ€“Small Cell Lung Cancer: Review of the Current Literature and Directions for the Future.â€ť
We are dedicated to providing in-depth articles of the most compelling research from the personalized medicine front for all of us involved in patient care. It is our hope this information assists you in providing the best care for your patients.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Just because whole genome sequencing can be done on a patientâ€™s tumor doesnâ€™t mean that this will translate to a patientâ€™s getting targeted therapy for identified genetic abnormalities, especially if that patient has pancreatic cancer. In the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial, no patient with an identified genetic [ Read More ]
Now that a number of targeted therapies are available for the treatment of cancer, one of the big questions is how best to combine them, especially for patients with few other treatment options. Preliminary study shows that combining the PARP inhibitor olaparib with the investigational PI3K inhibitor BKM120 achieves responses [ Read More ]